| Literature DB >> 27974702 |
Che-Yu Hsu1, Chun-Wei Wang2,3, Chia-Chun Kuo4, Yu-Hsuan Chen2,3, Keng-Hsueh Lan2,3, Ann-Lii Cheng3,5,6, Sung-Hsin Kuo2,3,5,6.
Abstract
In addition to clinical factors (tumor and node stage) and treatment factors (equivalent radiotherapy dose and chemotherapy regimen), we assessed whether different performances of various tumor volume measurements help predict the pathological complete response (pCR) of locally advanced rectal cancer (LARC) after preoperative concurrent chemoradiotherapy (CCRT). A total of 122 patients with LARC treated with a long course of CCRT, between December 2009 and March 2015, were enrolled in this bi-institutional study. Tumor delineation was based on standard T2-weighted magnetic resonance imaging or contrast-enhanced computed tomography before CCRT. Tumor compactness was defined as the ratio of the volume and the surface area. The tumor compactness-corrected TV (TCTV) was defined as the ratio of the real TV (RTV) and tumor compactness. Twenty-three (18.9%) patients had a pCR. Areas under the curve of the receiver operating characteristic for pCR prediction calculated using the RTV, cylindrical approximated TV (CATV), and TCTV were 0.724, 0.747, and 0.780, respectively. The prediction performance of TCTV was significantly more efficient than that of both RTV (P = 0.0057) and CATV (P = 0.0329). Multivariate logistic regression analysis revealed tumor compactness (P = 0.001), RTV (P = 0.042), and preoperative clinical nodal status (P = 0.044) as significant predictors of a pCR. In addition, poor tumor compactness was closely associated with lymphovascular space invasion (P = 0.008) and pathological nodal status (P = 0.003). For patients with LARC receiving preoperative CCRT, tumor compactness is a useful radiomic parameter for improving the volumetric based prediction model.Entities:
Keywords: chemoradiotherapy; pathologic complete remission; preoperative; rectal cancer; tumor compactness
Mesh:
Year: 2017 PMID: 27974702 PMCID: PMC5352371 DOI: 10.18632/oncotarget.13855
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Illustration for RTV, SA_RTV, and tumor compactness (RTV, real tumor volume; SA_RTV, surface area of RTV)
Baseline demographics of all patients
| Demographics (N = 122) | Number | Percentage | |
|---|---|---|---|
| Age | Median | 60.5 years | 23.0-92.4 years |
| Sex | Male | 83 | 68 % |
| Female | 39 | 32 % | |
| Clinical tumor stage (cT) | 0 | 0 | 0 |
| 1 | 0 | 0 | |
| 2 | 7 | 6 % | |
| 3 | 103 | 84 % | |
| 4 | 12 | 10 % | |
| Clinical node stage (cN) | 0 | 31 | 25.4% |
| 1 | 55 | 45.0% | |
| 2 | 36 | 29.5% | |
| Histology | Non-mucinous adenocarcinoma | 117 | 95.9% |
| Mucinous adenocarcinoma | 3 | 2.5% | |
| Adenocarcinoma with mucinous feature | 2 | 1.6% | |
| Pre-OP CCRT to Surgery (interval) | 3-6 weeks | 29 | 24 % |
| 6-8 weeks | 57 | 47 % | |
| >8 weeks | 36 | 29 % | |
| AAV | 0-5 cm | 60 | 49% |
| 5-10 cm | 57 | 47% | |
| 10-15 cm | 5 | 4 % | |
| CEA | Median | 3.53 | (0.3-102.5) |
| EQD2 | <45 | 20 | 16.4% |
| 45-50 | 40 | 32.8% | |
| >50 | 62 | 50.8% | |
| Chemotherapy | FL-based | 112 | 92% |
| Xeloda-based | 10 | 8 % |
Abbreviation: N, number; OP, operation; CCRT, chemoradiotherapy; EQD2, equivalent dose in 2 Gy fractions, AAV, above anal verge; FL, fluorouracil plus leucovorin
Characteristics and correlation analysis of tumor volumetry
| Tumor volumetry characteristics | Median | Range |
|---|---|---|
| Long axis | 5 cm | 1.5-15 cm |
| Diameter | 4.2 cm | 2.02-8.17 cm |
| CATV | 71.14 cm3 | 6.42-420 cm3 |
| RTV | 27.75 cm3 | 3.85-289.4 cm3 |
| Tumor compactness | 1.84 | 0.64-4.62 |
| CATV vs. RTV | R = 0.806 | R = 0.862 |
| CATV vs. Tumor compactness | R = -0.122 | R = -0.217 |
| RTV vs. tumor compactness | R = -0.04 | R = 0.129 |
Abbreviation: CATV, cylindrical approximated tumor volume; RTV, real tumor volume
Univariate and multivariate analysis for predictors of pCR after preoperative chemoradiotherapy
| Pretreatment | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| Clinical factor | HR | 95% CI | HR | 95% CI | ||
| Age | 0.982 | 0.301 | 0.949-1.016 | 0.967 | 0.160 | 0.922-1.013 |
| Female | 1.479 | 0.415 | 0.577-3.788 | 0.821 | 0.745 | 0.250-2.692 |
| Pre-OP CCRT to surgery (interval) | 0.907 | 0.746 | 0.502-1.639 | 1.009 | 0.979 | 0.497-2.050 |
| cT stage 4 vs. 2 and 3 | 0.364 | 0.345 | 0.045-2.969 | 7.378 | 0.254 | 0.238-228.39 |
| cN stage 1 and 2 vs. 0 | 2.252 | 0.099 | 0.860-5.889 | 3.701 | 0.044 | 1.033-13.259 |
| EQD2 > 50 Gy vs ≤ 50 Gy | 1.274 | 0.603 | 0.511-3.177 | 1.211 | 0.735 | 0.399-3.674 |
| FL-based vs Xeloda-based | 0.923 | 0.923 | 0.183-4.667 | 0.402 | 0.386 | 0.051-3.153 |
| RTV | 0.954 | 0.009 | 0.921-0.988 | 0.966 | 0.042 | 0.934-0.999 |
| Compactness | 3.368 | 0.001 | 1.672-6.786 | 4.103 | 0.001 | 1.801-9.346 |
| CATV | 0.981 | 0.005 | 0.967-0.994 | |||
Abbreviation: HR, hazard ratio; CI, confidence interval; OP, operation; CCRT, concurrent chemoradiotherapy; CATV, cylindrical approximated tumor volume; RTV, real tumor volume; EQD2, equivalent dose in 2 Gy fractions; FL, fluorouracil plus leucovorin; Xeloda, capectiabine.
Figure 2A. The blue, green, and yellow solid lines represent the ROC curve of the TCTV, CATV, and RTV-based prediction of the pCR
B. The blue, green, and yellow dashed lines represent the ROC curve of the TRP–TRG ≦ 1–TCTV, TRP–TRG ≦ 1–CATV, and TRP–TRG ≦ 1–RTV prediction of the pCR (ROC, receiver operating characteristic; TCTV, tumor compactness-corrected tumor volume; CATV, cylindrical approximated tumor volume; TRP, tumor response probability; TRG, tumor regression grade; pCR, pathologic complete remission).
Receiver operating characteristic curve analysis and comparison via pre-defined tumor volume
| AUC | 95% CI | |
|---|---|---|
| RTV | 0.724 | 0.636 to 0.801 |
| CATV | 0.747 | 0.660 to 0.821 |
| TCTV | 0.780 | 0.696 to 0.850 |
| RTV vs. CATV | ||
| Difference between AUC | 0.0224 | |
| Significance level | ||
| RTV vs. TCTV | ||
| Difference between AUC | 0.0553 | |
| Significance level | ||
| CATV vs. TCTV | ||
| Difference between AUC | 0.0329 | |
| Significance level | ||
Abbreviation: AUC, areas under the curve; CI, confidence interval; CATV, cylindrical approximated tumor volume; RTV, real tumor; TCTV, tumor compactness-corrected tumor volume; ROC, receiver operating characteristic.
Receiver operating characteristic curve analysis and comparison via the assistance of model
| AUC | 95% CI | |
|---|---|---|
| TRPTRG ≦1-CATV | 0.754 | 0.668 to 0.828 |
| TRPTRG ≦1-RTV | 0.738 | 0.650 to 0.813 |
| TRPTRG ≦1-TCTV | 0.795 | 0.713 to 0.863 |
| TRPTRG ≦1-CATV vs. TRPTRG ≦1-RTV | ||
| Difference between AUC | 0.0162 | |
| Significance level | ||
| TRPTRG ≦1-CATV vs. TRPTRG ≦1-TCTV | ||
| Difference between AUC | 0.0413 | |
| Significance level | ||
| TRPTRG ≦1-RTV vs. TRPTRG ≦1-TCTV | ||
| Difference between AUC | 0.0574 | |
| Significance level | ||
Abbreviation: AUC, areas under the curve; CI, confidence interval; TRP, tumor response probability; TRG, tumor regression grade; CATV, cylindrical approximated tumorvolume; RTV, real tumor; TCTV, tumor compactness-corrected tumor volume; ROC, receiver operating characteristic.
Figure 3The rectal tumors of one patient are contoured as the ROI_RTV on the axial images (here, T2-weighted and contrast-enhanced T1-weighted MRI) for each tumor-containing lesion
The red line encompasses the RTV area of every cross-sectional slice. The ROI_RTV_1 mm, the green line, was generated from the ROI_RTV with a 3-dimensional universal contraction of 1-mm length. The area between the outer red line and inner green line encompasses the outermost 1-mm layer volume as the surrogate of SA_RTV (RTV, real tumor volume; SA_RTV, surface area of RTV).